Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 26.14+0.5%5:20 PM EDTNews

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Going_2_Disney_World1/3/2018 3:47:45 PM
3 Recommendations

Recommended By

  Read Replies (1) of 46895
Music to our ears ???

Why 2018 is a make-or-break year for pharma

By Emma Court
Published: Jan 3, 2018 3:15 p.m. ET

Many drugmakers have neglected their pipelines, and will look to acquisitions to bolster them, one expert said

This year looks — at least on paper — like an unprecedentedly good setup for the pharmaceutical industry.

But behind the scientific breakthroughs, a Food and Drug Administration churning out approvals and drug-price regulation never materializing, the industry appears shockingly fragile.

Some of drugmakers’ most profitable products are aging, or simply old — nearly two decades old, in some cases — and staring down new competition.

Meanwhile, many big companies’ pipelines, typically a source of new development and the next billion-dollar drugs, are dry.

Acquisitions will thus become an integral part of the path foward, industry observers say, especially after a year of underwhelming merger-and-acquisition activity.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.